metformin has been researched along with Autism Spectrum Disorder in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications." | 9.27 | Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. ( Aman, MG; Anagnostou, EA; Arnold, LE; Chan, J; Handen, BL; Hastie Adams, R; Hollway, JA; Macklin, E; Marler, S; Newsom, C; Peleg, N; Sanders, KB; Veenstra-VanderWeele, J; Wong, T, 2018) |
| "A previous study reported on a 16-week placebo-controlled, randomized clinical trial (RCT) of metformin for weight stabilization in 61 children and adolescents 6 to 17 years old with autism spectrum disorder who were prescribed atypical antipsychotics." | 9.24 | A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Chan, J; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Williams, C; Wong, T, 2017) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 9.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 7.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| "Although further study is needed to support these null effects, the overall impression is that metformin does not affect memory in overweight youth with ASD who were taking atypical antipsychotic medications." | 5.27 | Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use. ( Aman, MG; Anagnostou, EA; Arnold, LE; Chan, J; Handen, BL; Hastie Adams, R; Hollway, JA; Macklin, E; Marler, S; Newsom, C; Peleg, N; Sanders, KB; Veenstra-VanderWeele, J; Wong, T, 2018) |
| "To evaluate the efficacy of metformin for weight gain associated with atypical antipsychotic medications in children and adolescents with ASD (defined in the protocol as DSM-IV diagnosis of autistic disorder, Asperger disorder, or pervasive developmental disorder not otherwise specified), aged 6 to 17 years." | 5.22 | Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. ( Aman, MG; Anagnostou, E; Arnold, LE; Brian, J; Butter, E; Capano, L; Hadjiyannakis, S; Handen, BL; Hellings, JA; Hollway, JA; Kettel, J; Macklin, EA; Mankad, D; Marler, S; McAuliffe-Bellin, S; Newsom, CR; Odrobina, D; Peleg, N; Sanders, KB; Shui, A; Tumuluru, R; Veenstra-VanderWeele, J; Wagner, A; Wong, T; Zakroysky, P, 2016) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| " Metformin has proven to be beneficial in the treatment of many syndromes, including autism spectrum disorder." | 4.12 | Metformin Alleviates Autistic-Like Behaviors Elicited by High-Fat Diet Consumption and Modulates the Crosstalk Between Serotonin and Gut Microbiota in Mice. ( Chen, Y; Deng, W; Ke, H; Li, F; Li, S; Li, Z; Lv, P; Wang, S, 2022) |
| " In this model, we also examined the medication effects of metformin (Met) which is known to ameliorate several symptoms of autism spectrum disorder (ASD)." | 4.12 | Effect of metformin in autistic BTBR T + Itpr3tf/J mice administered a high-fat diet. ( Chen, Y; Deng, W; Ke, H; Li, F; Li, Z; Lv, P; Wang, S, 2022) |
| " This study examined the effect of metformin on VPA-induced autism spectrum disorders in rats." | 3.96 | Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system. ( Adeyemi, OO; Balogun, AO; Ishola, IO, 2020) |
| " for their interest in our article on metformin and children with autism spectrum disorders (ASD) and for providing information about the MOBILITY study (a Patient-Centered Outcomes Research Institute (PCORI)-funded pragmatic clinical trial to examine the relative effectiveness of metformin plus healthy lifestyle instruction versus healthy lifestyle instruction alone)." | 3.88 | Dr. Handen et al. Reply. ( Aman, MG; Anagnostou, E; Handen, BL; Veenstra-VanderWeele, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Elnahas, EM | 1 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 1 |
| Deng, W | 2 |
| Ke, H | 2 |
| Wang, S | 2 |
| Li, Z | 2 |
| Li, S | 1 |
| Lv, P | 2 |
| Li, F | 2 |
| Chen, Y | 2 |
| Ishola, IO | 1 |
| Balogun, AO | 1 |
| Adeyemi, OO | 1 |
| Wink, LK | 1 |
| Adams, R | 1 |
| Pedapati, EV | 1 |
| Dominick, KC | 1 |
| Fox, E | 1 |
| Buck, C | 1 |
| Erickson, CA | 1 |
| Walkup, JT | 2 |
| Cottingham, E | 2 |
| Handen, BL | 5 |
| Anagnostou, E | 4 |
| Aman, MG | 5 |
| Sanders, KB | 4 |
| Chan, J | 3 |
| Hollway, JA | 3 |
| Brian, J | 2 |
| Arnold, LE | 3 |
| Capano, L | 2 |
| Williams, C | 1 |
| Hellings, JA | 2 |
| Butter, E | 2 |
| Mankad, D | 2 |
| Tumuluru, R | 2 |
| Kettel, J | 2 |
| Newsom, CR | 2 |
| Peleg, N | 3 |
| Odrobina, D | 2 |
| McAuliffe-Bellin, S | 2 |
| Marler, S | 3 |
| Wong, T | 3 |
| Wagner, A | 2 |
| Hadjiyannakis, S | 2 |
| Macklin, EA | 3 |
| Veenstra-VanderWeele, J | 5 |
| Macklin, E | 1 |
| Newsom, C | 1 |
| Hastie Adams, R | 1 |
| Anagnostou, EA | 2 |
| Higdon, C | 1 |
| Correll, CU | 1 |
| Crystal, S | 1 |
| Patel, N | 1 |
| DelBello, MP | 1 |
| Garfunkel, D | 1 |
| Salau, M | 1 |
| Adam, B | 1 |
| Coffey, BJ | 1 |
| Shui, A | 1 |
| Zakroysky, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder (ASD) While on Atypical Antipsychotic Medication[NCT03708614] | 10 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)[NCT01825798] | Phase 3 | 60 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder[NCT05916339] | Phase 4 | 500 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI z-score (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.02 |
| Metformin | -0.08 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.45 |
| Metformin | -0.21 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in BMI (kg/m2) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.52 |
| Metformin | -0.43 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (kg) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.80 |
| Metformin | 0.07 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | centimetres (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 1.06 |
| Metformin | -0.63 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-wk change in weight (z-score) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 0.04 |
| Metformin | -0.10 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in gluclose (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -2.41 |
| Metformin | -3.06 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in HDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.98 |
| Metformin | 3.27 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change insulin fasting (µIU/mL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 2.95 |
| Metformin | 1.97 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in LDL (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -0.41 |
| Metformin | -4.41 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change total cholesterol (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | -3.29 |
| Metformin | -1.05 |
(NCT01825798)
Timeframe: Baseline, 16 Weeks
| Intervention | 16-week change in triglycerides (mg/dL) (Mean) |
|---|---|
| Placebo Hydrochloride Oral Solution | 6.18 |
| Metformin | 5.74 |
1 review available for metformin and Autism Spectrum Disorder
| Article | Year |
|---|---|
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
4 trials available for metformin and Autism Spectrum Disorder
| Article | Year |
|---|---|
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
A Randomized, Placebo-Controlled Trial of Metformin for the Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorder: Open-Label Extension.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
Effects of Metformin on Spatial and Verbal Memory in Children with ASD and Overweight Associated with Atypical Antipsychotic Use.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Double-Blind Method; Female; Huma | 2018 |
Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder.
Topics: Adolescent; Ataxia Telangiectasia Mutated Proteins; Autism Spectrum Disorder; Child; Double-Blind Me | 2019 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Body Mass Index; Child; Dose-Response Re | 2016 |
10 other studies available for metformin and Autism Spectrum Disorder
| Article | Year |
|---|---|
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Metformin Alleviates Autistic-Like Behaviors Elicited by High-Fat Diet Consumption and Modulates the Crosstalk Between Serotonin and Gut Microbiota in Mice.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Diet, High-Fat; Gastrointestinal Microbiome; M | 2022 |
Effect of metformin in autistic BTBR T + Itpr3tf/J mice administered a high-fat diet.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Diet, High-Fat; Disease Models, Animal; Metfor | 2022 |
Novel potential of metformin on valproic acid-induced autism spectrum disorder in rats: involvement of antioxidant defence system.
Topics: Animals; Anticonvulsants; Antioxidants; Autism Spectrum Disorder; Disease Models, Animal; Female; Hy | 2020 |
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Female; Humans; Hypoglycemic Agen | 2017 |
Antipsychotic-Induced Weight Gain and Metformin.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2017 |
Mobility for All?
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Double-Blind Method; Humans; Metf | 2018 |
Dr. Handen et al. Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Humans; Metformin; Overweight; We | 2018 |
Drs. Walkup and Cottingham Reply.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Metformin; Overweight; Weight Ga | 2018 |
Metformin in an Adolescent with Significant Weight Gain.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autism Spectrum Disorder; Humans; Hypoglycemic Agents; | 2015 |